The case in front of me: semaglutide · four weeks · 25 °C.
The failure mode I am trying to avoid is making this decision emotionally.
I have twelve months in view and I would like the plan to survive that long.
How would you structure this, and what thresholds would you set in advance?
On the detail: the failure mode here is publishing a result that applies to the tested vial alone while implying it applies to the entire lot.
The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.
It helps to be literal here: published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.
If testing multiple vials, state how many you tested and why you chose those vials.
edited 9 Aug 2026 by juan_esquivel — fixed an arithmetic slip in the third paragraph
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemBatch testing establishes what can be claimed about the lot as a whole, and the sample size determines how much you can actually claim.
If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.
Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
In practice, the single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.
If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.
It helps to be literal here: acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.
Assume segregation is possible, and design your sampling to catch it if it exists.
Thermal history during shipping is different for every vial, so a lot that experienced thermal abuse may have internal variation even if it was originally homogeneous.
If the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.
If testing multiple vials, state how many you tested and why you chose those vials.
Two vials tested from a lot of ten is very different from two vials tested from a lot of ten thousand, and most certificates do not state the lot size.
A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.
Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.